Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study

Nagashima, Hirotaka; Suzuki, Miyako; Araki, S; Yamabe, Takaharu; Muto, Chieko

doi:10.1016/j.joca.2011.09.006

Cited by 77 publications

(79 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tanezumab, a humanized monoclonal antibody for NGF, provided significant pain relief for OA patients when administered alone or as an adjunct therapy [85][86][87][88][89][90][91]. Conversely, the direct application of NGF caused hyperalgesia and allodynia in both rats [92] and humans [93].…”

Section: Nerve Growth Factormentioning

confidence: 99%

Mechanisms and Mediators That Drive Arthritis Pain

Krustev

Rioux

McDougall

2015

Curr Osteoporos Rep

View full text Add to dashboard Cite

There are over 100 different types of arthritis and each can differ greatly in their aetiology and pathophysiology; however, one characteristic that is common to all arthritic conditions is joint pain. Musculoskeletal pain is the leading cause of disability in the world, and the number one reason arthritis patients visit their primary care physician. Despite the prevalence and burden of arthritis pain, current analgesics lack sufficient efficacy and are plagued by multiple adverse side effects. In this review, we outline the current landscape of research concerning joint pain, drawing from both preclinical and clinical studies. Specifically, this review is a discussion of the different neurophysiological processes that occur during joint disease and how inflammatory and neuropathic aspects contribute to the development of arthritis pain.

show abstract

Section: Nerve Growth Factormentioning

confidence: 99%

Mechanisms and Mediators That Drive Arthritis Pain

Krustev

Rioux

McDougall

2015

Curr Osteoporos Rep

View full text Add to dashboard Cite

show abstract

“…Currently, there are no approved biological therapies for patients with OA. Recent studies showed significant improvement in pain and function of knee OA with tanezumab; however, it should be mentioned that mild to moderate AEs occurred [32][33][34][35].…”

Section: Tanezumabmentioning

confidence: 99%

“…During the neonatal period, NGF supports development of the sensory neurons; in adults, NGF is essential in raising awareness of the nociceptor function of neurons with the onset of pain and hyperalgesia in chronic pain. This function may be observed after injury and inflammation, when NGF expression ultimately increases, including in patients with OA, who also express high levels of NGF in their joints [32][33][34][35].…”

Section: Tanezumabmentioning

confidence: 99%

“…In their final conclusions, the study investigators reported continued pain relief and improvement in SGA, with a low incidence of side effects. Nagashima et al [34] investigated the use of tanezumab in 83 patients with moderate and severe OA; the end points included incidence of AEs and change from baseline to week 8 in pain intensity and WOMAC score. At the eighth week, patients in the tanezumab group reported improvement in index knee pain during walking, pain in the past 24 hours, current index knee pain, stiffness, and knee function compared with the placebo group.…”

Section: Tanezumabmentioning

confidence: 99%

See 1 more Smart Citation

Update on biological therapies for knee injuries: osteoarthritis

Pintan

Oliveira

Lenza

et al. 2014

Curr Rev Musculoskelet Med

View full text Add to dashboard Cite

Osteoarthritis (OA) is a progressive disease that causes functional impairment of the joints. Chronic forms of knee OA have been increasing worldwide, limiting patients' quality of life. Recent studies have sought to increase effectiveness and quality in the development of new therapies, such as platelet-rich plasma, hyaluronic acid, stem cells, and nuclear factor κB, aimed principally at reducing proinflammatory activity, pain, and degeneration of the knee joints. The goal of this review is to present an update on biological therapies for knee OA and to provide guidance for future OA studies.

show abstract

“…Minimal evidence of AEs with repeat injections was shown. Nagashima et al [ 129 ] investigated the use of tanezumab in 83 patients with moderate and severe OA -all AEs were considered mild to moderate in severity. Overall, the use of tanezumab was considered safe and well tolerated.…”

Section: Tanezumab: Ngf Blockermentioning

confidence: 99%

Safety Profile of Current OA Therapies: Evidence from Clinical Trials

Perruccio

Chandran

2015

Osteoarthritis

View full text Add to dashboard Cite

Key Points• The pharmacologic management of osteoarthritis (OA) is primarily targeted at managing symptoms, and there are several classes of agents in current use. Many of these agents, though effi cacious, are associated with adverse events.• Over time, the complement of adverse events under investigation has broadened, expanding from gastrointestinal (GI) events to also include cardiovascular (CV) and neurological events.• Pharmacologic management in OA is challenging, especially in older adults particularly due to comorbidities, different causes of pain, and a high rate of polypharmacy. In addition, while OA is treated as a homogeneous diagnostic category, there is evidence to suggest otherwise. This has implications for the pharmacologic management of OA and design of drug trials.212

show abstract

Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study

Abstract: Tanezumab was safe and generally well tolerated and may improve pain symptoms in Japanese patients with moderate to severe osteoarthritis of the knee. CLINICALTRIALS.GOV IDENTIFIER: NCT00669409.

Cited by 77 publications

References 20 publications

Mechanisms and Mediators That Drive Arthritis Pain

Mechanisms and Mediators That Drive Arthritis Pain

Update on biological therapies for knee injuries: osteoarthritis

Safety Profile of Current OA Therapies: Evidence from Clinical Trials

Contact Info

Product

Resources

About